Vaxil Bio Ltd. is a biotechnology company specializing in drug discovery and development using signal peptides to target infectious diseases and cancer, with its lead candidate being ImMucin. The company shows strong financial health with a high current ratio of 104.17 and zero debt, indicating excellent liquidity and minimal financial risk. However, its low market cap of $517.92K and stagnant stock price raise concerns about market confidence and growth potential. While the return on equity and assets are positive, the overall valuation appears low relative to its financial stability.
Loading financial metrics...
Company posted a loss of $-99K over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $155K over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 104.2x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)